DNA Methylation Patterns and Relapse in Polymyalgia Rheumatica After Steroid Tapering
Studies whether DNA methylation changes can predict relapse in 50 people with polymyalgia rheumatica.
Key facts
- Who runs it
- Dartmouth-Hitchcock Medical Center
- Where
- Lebanon, United StatesSee the site
- Trial code
- Registry title
- DNA Methylation in PMR
- Status
- Recruiting
- People taking part
- 50 people, planned
- Started
- 31 Aug 2026
- Expected to end
- 1 Apr 2027
- Type of study
- Observational, 2 groups
- Record updated
- 16 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with polymyalgia rheumatica (PMR) whose disease is stable while on prednisone. It also takes healthy volunteers of similar age and sex as a comparison group.
- Age
- 50 to 89 years
- Sex
- All sexes
- Disease stage
- PMR diagnosis with stable disease and normal inflammation blood tests (ESR and CRP).
- Earlier treatment
- Taking ≥10mg of prednisone or prednisone equivalent at the time of joining.
- Biomarker or test result
- Normal CRP: <1.0 mg/dL (or usually <3 mg/L). Normal ESR: 0-20 mm/hr for men ≥50 years, 0-30 mm/hr for women ≥50 years.
Main reasons for not taking part
- History of giant cell arteritis (GCA) at the same time
- Other rheumatic diseases such as lupus, psoriatic arthritis, osteoarthritis, scleroderma or Sjogren's
- Active cancer seen on imaging or lab tests
- Current infection
- Surgery within the past 6 months
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Anyone ≥50-89 years old Taking ≥10mg of prednisone or prednisone equivalent at time of enrollment with a stable disease normal ESR and CRP (inflammation markers) which would indicate presence of inflammation or not
- CRP: <1.0 mg/dL (some labs report in mg/L → normal is usually <3 mg/L)
- ESR:
- Men ≥50 years: 0-20 mm/hr
- Women ≥50 years: 0-30 mm/hr Have a PMR diagnosis Able to provide written consent
Who cannot take part
- History of concomitant Giant cell arteritis (GCA) any other rheumatological disorders like lupus, arthritis (psoriatic, osteo), scleroderma, sjogrens Active malignancy- presence of tumor by imaging or labs Infection- infection can cause increased levels of innate immune cells making it difficult to differentiate between disease and infection recent surgery- within the past 6 months
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 50 and 89 years old?
This trial is currently available in United States.
- Dartmouth Hitchcock Medical CenterLebanon, United StatesContact: Vivekanand Tiwari, MDTaking people
About the trial
What the trial wants to find out
Polymyalgia Rheumatica (PMR) is treated with corticosteroids; however, long-term treatment is not feasible due to side effects. Withdrawal of corticosteroids causes a subset of patients to relapse, and there is no current way to understand what underlies this. Our research team has preliminary data from a small clinical study that indicates that different immune effector dynamics during the tapering of steroids correlate with relapse. This was achieved using the DNA methylation-specific immune cell profiling methods that Dr. Christensen has pioneered. What is proposed is a larger prospective study of 50 PMR patients to validate differences in CD4 and CD8 memory cells as a predictor of relapse. Finally, we also focus on the Glucocorticoid Methylation Index (GCMI), which is a collection of 28 CpG islands that are methylated in response to corticosteroids. This will allow our team to determine the predictive power of the GCMI for PMR.
The 2 groups in the trial
- PMR diagnosed
individuals who have a PMR diagnosis
- Healthy Volunteers
Healthy individuals, without a PMR diagnosis, which will allow age and sex matches with the PMR diagnosed cohort.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- DNA Methylation in PMR
- Plain-language title
- DNA Methylation Patterns and Relapse in Polymyalgia Rheumatica After Steroid TaperingGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT07748195, who can take part
- Record updated
- 16 November 2026